Insider filing · AXGN
Amy McBride Wendell
Director
profile →
Axogen, Inc.
AXGN · Healthcare · 30 filings in 24 months
ticker →
Amy McBride Wendell sold $1.3M of Axogen (AXGN)
Executed Dec 16 2025, disclosed Dec 17 2025, 1 day later.
Value, as filed
$1.3M
43,684 sh across 3 lots
Executed
Dec 16 2025
the trade date, as filed
Disclosed
Dec 17 2025
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
AWAmy McBride Wendell (Director) filed 3 Form 4 reports in the trailing twelve months (1 purchase, 2 sales), most often in Axogen, Inc. (AXGN). Across 1 priced purchase filing, the average 21-session return was -4.5% from execution and -2.2% from disclosure (delay-adjusted; derived). The largest single filing was $1.3M of AXGN (43,684 sh across 3 lots, as filed), executed Dec 16 2025.
The name
AXGNHealthcare · Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerv…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Amy McBride Wendell in AXGN
AXGNSALE
Axogen, Inc.
$647K13,353 sh × $48.42
Exec Aug 11
Filed Aug 12 · 4:12 PM ET AXGNSALE Axogen, Inc. $100K
5,000 sh × $20.02
Exec Mar 3 2025
Filed Mar 5 2025 · 5:30 PM ET